Top

Neurological Sciences

Published in:

Open Access 24-05-2022 | Tremor | Original Article

Lower serum triglyceride levels linked to more severe motor performance in Parkinson’s disease

Authors: Meimei Zhang, Huimin Chen, Genliang Liu, Xuemei Wang, Zhan Wang, Tao Feng, Yumei Zhang

Published in: Neurological Sciences | Issue 9/2022

Abstract

Introduction

Emerging evidence has suggested that lipid metabolism is correlated with Parkinson’s disease (PD) onset and progression. However, the effect of lipid metabolism on motor performance in PD patients is still unknown. This study estimated the association between lipid profiles and the severity of motor performance in PD.

Methods

This cross-sectional study enrolled 279 idiopathic PD patients from the Department of Neurology of Beijing Tiantan Hospital from May 2016 to August 2018. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (Apo-A1), and apolipoprotein B (Apo-B) levels were detected in fast serum samples. Motor performance was assessed by Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III (MDS-UPDRS III) total scores and subscores in these patients. The associations of lipid profiles with motor performance were analyzed using multivariable linear regression models.

Results

Compared to males, females with PD exhibited significantly higher serum TC, LDL-C, HDL-C, Apo-A1, and Apo-B levels. When accounting for covariates, lower serum TG levels were significantly associated with higher MDS-UPDRS III total scores and gait/postural instability subscores. Additionally, the univariate linear regression model showed that in males with PD, serum HDL-C or Apo-A1 levels were significantly associated with tremor subscores.

Conclusion

Lower serum TG levels were associated with more severe motor performance in patients with PD and TG may be a potential predictive biomarker for motor performance in PD patients.

Available only for authorised users

Rana A, Siddiqui I, Mosabbir A, Qureshi A, Fattah A, Awan N (2014) Is action tremor in Parkinson’s disease related to resting tremor? Neurol Res 36:107–111. https://doi.org/10.1179/1743132813y.0000000274CrossRefPubMed

Dirkx M, Zach H, Bloem B, Hallett M, Helmich R (2018) The nature of postural tremor in Parkinson disease. Neurology 90:e1095–e1103. https://doi.org/10.1212/wnl.0000000000005215CrossRefPubMedPubMedCentral

Kalia L, Lang A (2015) Parkinson’s disease. Lancet (London, England) 386:896–912. https://doi.org/10.1016/s0140-6736(14)61393-3CrossRef

Nakamura A, Otani K, Shichita T (2020) Lipid mediators and sterile inflammation in ischemic stroke. Int Immunol 32:719–725. https://doi.org/10.1093/intimm/dxaa027CrossRefPubMed

Rozani V, Gurevich T, Giladi N, El-Ad B, Tsamir J, Hemo B, Peretz C (2018) Higher serum cholesterol and decreased Parkinson’s disease risk: a statin-free cohort study. Mov Disord 33:1298–1305. https://doi.org/10.1002/mds.27413CrossRefPubMed

Fang F, Zhan Y, Hammar N, Shen X, Wirdefeldt K, Walldius G, Mariosa D (2019) Lipids, apolipoproteins, and the risk of parkinson disease. Circ Res 125:643–652. https://doi.org/10.1161/CIRCRESAHA.119.314929CrossRefPubMed

Guo X, Song W, Chen K, Chen X, Zheng Z, Cao B, Huang R, Zhao B, Wu Y, Shang H (2015) The serum lipid profile of Parkinson’s disease patients: a study from China. Int J Neurosci 125:838–844. https://doi.org/10.3109/00207454.2014.979288CrossRefPubMed

Huang X, Ng S, Chia N, Acharyya S, Setiawan F, Lu Z, Tan Y, Ng E, Wen M, Ng A, Tay K, Au W, Tan E, Tan L (2018) Higher serum triglyceride levels are associated with Parkinson’s disease mild cognitive impairment. Mov Disord 33:1970–1971. https://doi.org/10.1002/mds.27521CrossRefPubMed

Dong MX, Wei YD, Hu L (2021) The disturbance of lipid metabolism is correlated with neuropsychiatric symptoms in patients with Parkinson’s disease. Chem Phys Lipids 239:105112. https://doi.org/10.1016/j.chemphyslip.2021.105112CrossRefPubMed

10.

Bakeberg MC, Gorecki AM, Kenna JE, Jefferson A, Byrnes M, Ghosh S, Horne MK, McGregor S, Stell R, Walters S, Mastaglia FL, Anderton RS (2021) Elevated HDL levels linked to poorer cognitive ability in females with Parkinson’s disease. Front Aging Neurosci 13:656623. https://doi.org/10.3389/fnagi.2021.656623CrossRefPubMedPubMedCentral

11.

Choe CU, Petersen E, Lezius S, Cheng B, Schulz R, Buhmann C, Potter-Nerger M, Daum G, Blankenberg S, Gerloff C, Schwedhelm E, Zeller T (2021) Association of lipid levels with motor and cognitive function and decline in advanced Parkinson’s disease in the Mark-PD study. Parkinsonism Relat Disord 85:5–10. https://doi.org/10.1016/j.parkreldis.2021.02.007CrossRefPubMed

12.

Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS (2015) Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord 30:1648–1656. https://doi.org/10.1002/mds.26290CrossRefPubMedPubMedCentral

13.

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W, Obeso J, Marek K, Litvan I, Lang A, Halliday G, Goetz C, Gasser T, Dubois B, Chan P, Bloem B, Adler C, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424CrossRefPubMed

14.

Tomlinson C, Stowe R, Patel S, Rick C, Gray R, Clarke C (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653. https://doi.org/10.1002/mds.23429CrossRefPubMed

15.

Sleeman I, Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo TK, Burn DJ (2019) Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson’s disease. J Parkinsons Dis 9:351–359. https://doi.org/10.3233/JPD-181535CrossRefPubMedPubMedCentral

16.

Contois J, Wu A, Li Z, Feroze A, Grunenberger F, Haller J, deGroot L, Lammi-Keefe C (2000) Distribution of serum apolipoproteins A-I and B and lipoprotein(a) in European elderly. The SENECA study. Clin Chim Acta 295:1–12. https://doi.org/10.1016/s0009-8981(00)00187-xCrossRefPubMed

17.

Lyu L, Yeh C, Lichtenstein A, Li Z, Ordovas J, Schaefer E (2001) Association of sex, adiposity, and diet with HDL subclasses in middle-aged Chinese. Am J Clin Nutr 74:64–71. https://doi.org/10.1093/ajcn/74.1.64CrossRefPubMed

18.

Saaksjarvi K, Knekt P, Mannisto S, Lyytinen J, Heliovaara M (2015) Prospective study on the components of metabolic syndrome and the incidence of Parkinson’s disease. Parkinsonism Relat Disord 21:1148–1155. https://doi.org/10.1016/j.parkreldis.2015.07.017CrossRefPubMed

19.

Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37:1184–1188. https://doi.org/10.1161/01.STR.0000217384.03237.9cCrossRefPubMed

20.

Wei Q, Wang H, Tian Y, Xu F, Chen X, Wang K (2013) Reduced serum levels of triglyceride, very low density lipoprotein cholesterol and apolipoprotein B in Parkinson’s disease patients. PLoS ONE 8:e75743. https://doi.org/10.1371/journal.pone.0075743CrossRefPubMedPubMedCentral

21.

Wong M, Braidy N, Poljak A, Pickford R, Thambisetty M, Sachdev P (2017) Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers. Alzheimer’s Dementia 13:810–827. https://doi.org/10.1016/j.jalz.2017.01.008CrossRefPubMed

22.

Gómez-Soler M, Cordobilla B, Morató X, Fernández-Dueñas V, Domingo J, Ciruela F (2018) Triglyceride form of docosahexaenoic acid mediates neuroprotection in experimental parkinsonism. Front Neurosci 12:604. https://doi.org/10.3389/fnins.2018.00604CrossRefPubMedPubMedCentral

23.

Mayurasakorn K, Niatsetskaya Z, Sosunov S, Williams J, Zirpoli H, Vlasakov I, Deckelbaum R, Ten V (2016) DHA but not EPA emulsions preserve neurological and mitochondrial function after brain hypoxia-ischemia in neonatal mice. PLoS ONE 11:e0160870. https://doi.org/10.1371/journal.pone.0160870CrossRefPubMedPubMedCentral

24.

Berland C, Montalban E, Perrin E, Di Miceli M, Nakamura Y, Martinat M, Sullivan M, Davis XS, Shenasa MA, Martin C, Tolu S, Marti F, Caille S, Castel J, Perez S, Salinas CG, Morel C, Hecksher-Sorensen J, Cador M, Fioramonti X, Tschop MH, Laye S, Venance L, Faure P, Hnasko TS, Small DM, Gangarossa G, Luquet SH (2020) Circulating triglycerides gate dopamine-associated behaviors through DRD2-expressing neurons. Cell Metab 31:773-790 e711. https://doi.org/10.1016/j.cmet.2020.02.010CrossRefPubMedPubMedCentral

25.

Ng KF, Anderson S, Mayo P, Aung HH, Walton JH, Rutledge JC (2016) Characterizing blood-brain barrier perturbations after exposure to human triglyceride-rich lipoprotein lipolysis products using MRI in a rat model. Magn Reson Med 76:1246–1251. https://doi.org/10.1002/mrm.25985CrossRefPubMed

26.

Nägga K, Gustavsson A, Stomrud E, Lindqvist D, van Westen D, Blennow K, Zetterberg H, Melander O, Hansson O (2018) Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. Neurology 90:e73–e81. https://doi.org/10.1212/wnl.0000000000004749CrossRefPubMedPubMedCentral

27.

Bell J, Santos Ferreira D, Fraser A, Soares A, Howe L, Lawlor D, Carslake D, Davey Smith G, O’Keeffe L (2021) Sex differences in systemic metabolites at four life stages: cohort study with repeated metabolomics. BMC Med 19:58. https://doi.org/10.1186/s12916-021-01929-2CrossRefPubMedPubMedCentral

28.

Knopp R, Paramsothy P, Retzlaff B, Fish B, Walden C, Dowdy A, Tsunehara C, Aikawa K, Cheung M (2006) Sex differences in lipoprotein metabolism and dietary response: basis in hormonal differences and implications for cardiovascular disease. Curr Cardiol Rep 8:452–459. https://doi.org/10.1007/s11886-006-0104-0CrossRefPubMed

29.

Link J, Reue K (2017) Genetic basis for sex differences in obesity and lipid metabolism. Annu Rev Nutr 37:225–245. https://doi.org/10.1146/annurev-nutr-071816-064827CrossRefPubMedPubMedCentral

30.

Emamzadeh FN, Allsop D (2017) Alpha-synuclein interacts with lipoproteins in plasma. J Mol Neurosci 63:165–172. https://doi.org/10.1007/s12031-017-0967-0CrossRefPubMedPubMedCentral

31.

Galvagnion C (2017) The role of lipids interacting with α-synuclein in the pathogenesis of Parkinson’s disease. J Parkinsons Dis 7:433–450. https://doi.org/10.3233/jpd-171103CrossRefPubMed

32.

Céspedes Rubio Á, Pérez-Alvarez M, Lapuente Chala C, Wandosell F (2018) Sex steroid hormones as neuroprotective elements in ischemia models. J Endocrinol 237:R65–R81. https://doi.org/10.1530/joe-18-0129CrossRefPubMed

33.

Houser M, Tansey M (2017) The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinson’s Dis 3:3. https://doi.org/10.1038/s41531-016-0002-0CrossRef

34.

Pajares M, Rojo IA, Manda G, Boscá L, Cuadrado A (2020) Inflammation in Parkinson’s disease: mechanisms and therapeutic implications. Cells 9. https://doi.org/10.3390/cells9071687

35.

Nazir S, Jankowski V, Bender G, Zewinger S, Rye K, van der Vorst E (2020) Interaction between high-density lipoproteins and inflammation: function matters more than concentration! Adv Drug Deliv Rev 159:94–119. https://doi.org/10.1016/j.addr.2020.10.006CrossRefPubMed

36.

Luca A, Monastero R, Cicero C, Baschi R, Donzuso G, Mostile G, Restivo V, Di Giorgi L, Caccamo M, Zappia M, Nicoletti A (2022) Executive functioning and serum lipid fractions in Parkinson’s disease-a possible sex-effect: the PACOS study. J Neural Transm (Vienna, Austria : 1996). https://doi.org/10.1007/s00702-022-02460-1

37.

Vekic J, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Bogavac-Stanojevic N, Memon L, Spasic S (2009) Small, dense LDL cholesterol and apolipoprotein B: relationship with serum lipids and LDL size. Atherosclerosis 207:496–501. https://doi.org/10.1016/j.atherosclerosis.2009.06.035CrossRefPubMed

38.

Klemann C, Martens G, Sharma M, Martens M, Isacson O, Gasser T, Visser J, Poelmans G (2017) Integrated molecular landscape of Parkinson’s disease. NPJ Parkinson’s Dis 3:14. https://doi.org/10.1038/s41531-017-0015-3CrossRef

Title: Lower serum triglyceride levels linked to more severe motor performance in Parkinson’s disease
Authors: Meimei Zhang
Huimin Chen
Genliang Liu
Xuemei Wang
Zhan Wang
Tao Feng
Yumei Zhang
Publication date: 24-05-2022
Publisher: Springer International Publishing
Keywords: Tremor
Parkinson's Disease
Movement Disorder
Published in: Neurological Sciences / Issue 9/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-06113-9

At a glance: The STEP trials

Springer Medicine

Lower serum triglyceride levels linked to more severe motor performance in Parkinson’s disease

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2022

REM sleep behavior disorder as a remote precedent to Creutzfeldt-Jakob disease

Cognition and motor phenotypes in ALS: a retrospective study

Parkinsonism in idiopathic normal pressure hydrocephalus: is it time for defining a clinical tetrad?

The pupil and myself: pupil dilation during retrieval of self-defining memories

Floating aortic arch thrombus involving the left common carotid artery complicated with ischemic stroke associated with cocaine use

Gender differences in obsessive–compulsive disorder traits among chronic migraine patients